Peer review of the pesticide risk assessment of the active substance fluazaindolizine Authors: European Food Safety Authority (EFSA), Fernando Álvarez, Maria Arena, Athanasiou Dionysia, Domenica Auteri, Sofia Batista Leite, Marco Binaglia, Anna Federica Castoldi, Arianna Chiusolo, Angelo Colagiorgi, Mathilde Colas, Federica Crivellente, Chloe De Lentdecker, Isabella De Magistris, Gabriella Fait, Franco Ferilli, German Giner Santonja, Varvara Gouliarmou, Alessio Ippolito, Frederique Istace, Dimitra Kardassi, Aude Kienzler, Anna Lanzoni, Roberto Lava, Renata Leuschner, Alberto Linguadoca, Mariano Lopez Romano, Jochem Louisse, Christopher Lythgo, Oriol Magrans, Iris Mangas, Silvia Mazzega, Andrea Mioč, Ileana Miron, Tunde Molnar, Laura Padovani, Vincenzo Padricello, Martina Panzarea, Juan Manuel Parra Morte, Simone Rizzuto Published: 2026 ABSTRACT AbstractThe conclusions of the European Food Safety Authority (EFSA) following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, Malta, for the pesticide active substance fluazaindolizine. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative uses of fluazaindolizine as a nematicide on cucurbits with edible peel (cucumber, courgette) and carrot. The reliable endpoints, appropriate for use in regulatory risk assessment are presented. Missing information identified as being required by the regulatory framework is listed. Concerns are identified. SUMMARY Fluazaindolizine is a new active substance for which, in accordance with Article 7 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the rapporteur Member State (RMS), Malta, received an application from Corteva Agriscience International Sàrl on 15 March 2021 for approval. Complying with Article 9 of the Regulation, the completeness of the dossier was checked by the RMS and the date of admissibility of the application was recognised as being 13 May 2021. An initial evaluation of the dossier on fluazaindolizine was provided by the RMS in the draft assessment report (DAR) and subsequently, a peer review of the pesticide risk assessment on the RMS evaluation was conducted by EFSA in accordance with Article 12 of Regulation (EC) No 1107/2009. The following conclusions are derived. The uses of fluazaindolizine according to the representative uses as a nematicide on cucurbits with edible peel (cucumber, courgette) in greenhouses (permanent) via drip irrigation and on carrot in the field via hydraulic ground directed nozzles seedbed application, as proposed at EU level, result in a sufficient nematocidal efficacy against the target pests. In the identity section, several data gaps were identified leading to the reference specification proposal not being finalised. The assessment of the data package revealed no issues that could not be finalised or that need to be included as critical areas of concern with respect to physical, chemical and technical properties of fluazaindolizine or the formulation for representative uses and analytical methods. In the area of mammalian toxicology and non‐dietary exposure, no critical areas of concern were identified. Fluazaindolizine potential for phototoxicity and photomutagenicity could not be finalised. A data gap was identified for the assessment of the aneugenicity of the groundwater metabolite IN‐VM862 leading to its groundwater relevance assessment not being finalised. Lastly, the risk assessment for the volatile metabolite IN‐VM862 to humans could not be finalised pending information on its inhalation toxicity profile and relevant PECair. In the residue section, several data gaps were identified, leading to a consumer risk assessment not being finalised. A very preliminary dietary exposure assessment was calculated for primary crops and honey only. Due to data gaps identified in the environmental fate and behaviour section (see below) the consumer risk assessment from the consumption of drinking water could not be finalised for all the representative uses. In the area of environmental fate and behaviour, a data gap was identified leading to assessments not being finalised regarding information on the effect of water treatment processes on the nature of residues of both the active substance and its identified metabolites potentially present in surface water, when surface water is abstracted for drinking water, as well as for the groundwater metabolites that may be concluded as non‐relevant, when groundwater is abstracted for drinking water. Investigation was missing on the potential formation of trifluoroacetic acid (TFA) in environmental compartments as a result of the metabolic degradation of fluazaindolizine. The surface water exposure assessment could not be finalised due to the presence of two unidentified chromatographically resolved peaks in natural water samples from the aqueous photolysis study. In the area of ecotoxicology issues that could not be finalised or that needed to be included as critical areas of concern were not identified. With regard to the endocrine disruption (ED) properties, based on the available data and assessment, it is concluded that fluazaindolizine does not meet the ED criteria for human and non‐target organisms according to points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605. BACKGROUND Regulation (EC) No 1107/2009 of the European Parliament and of the Council 1 (hereinafter referred to as ‘the Regulation’) lays down, inter alia, the detailed rules as regards the procedure and conditions for approval of active substances. This regulates for the European Food Safety Authority (EFSA) the procedure for organising the consultation of Member States and the applicant(s) for comments on the initial evaluation in the draft assessment report (DAR), provided by the rapporteur Member State (RMS), and the organisation of an expert consultation, where appropriate. In accordance with Article 12 of the Regulation, EFSA is required to adopt a conclusion on whether an active substance can be expected to meet the approval criteria provided for in Article 4 of the Regulation (also taking into consideration recital (10) of the Regulation) within 120 days from the end of the period provided for the submission of written comments, subject to an extension of 30 days where an expert consultation is necessary, and a further extension of up to 150 days where additional information is required to be submitted by the applicant(s) in accordance with Article 12(3). Fluazaindolizine is a new active substance for which, in accordance with Article 7 of the Regulation, the RMS, Malta (hereinafter referred to as the ‘RMS’), received an application from Corteva Agriscience International Sàrl on 15 March 2021 for approval of the active substance fluazaindolizine. Complying with Article 9 of the Regulation, the completeness of the dossier was checked by the RMS and the date of admissibility of the application was recognised as being 13 May 2021. The RMS provided its initial evaluation of the dossier on fluazaindolizine in the DAR, which was received by EFSA on 19 June 2023 (Malta, 2023). The peer review was initiated on 11 September 2023 by dispatching the DAR to the Member States and the applicant, Corteva Agriscience International Sàrl, for consultation and comments. EFSA also provided comments. In addition, EFSA conducted a public consultation on the DAR. The comments received were collated by EFSA and forwarded to the RMS for compilation and evaluation in the format of a reporting table. The applicant was invited to respond to the comments in column 3 of the reporting table. The comments and the applicant's response were evaluated by the RMS in column 3. The need for expert consultation and the necessity for additional information to be submitted by the applicant in accordance with Article 12(3) of the Regulation were considered in a telephone conference between EFSA, the RMS and ECHA on 13 February 2024. On the basis of the comments received, the applicant's response to the comments and the RMS's evaluation thereof, it was concluded that additional information should be requested from the applicant, and that EFSA should conduct an expert consultation in the areas of mammalian toxicology, residues, environmental fate and behaviour, and ecotoxicology. The outcome of the telephone conference, together with EFSA's further consideration of the comments is reflected in the conclusions set out in column 4 of the reporting table. All points that were identified as unresolved at the end of the comment evaluation phase and which required further consideration, including those issues to be considered in an expert consultation, were compiled by EFSA in the format of an evaluation table. The conclusions arising from the consideration by EFSA, and as appropriate by the RMS, of the points identified in the evaluation table, together with the outcome of the expert consultation and the written consultation on the assessment of additional information, where these took place, were reported in the final column of the evaluation table. In accordance with Article 12 of the Regulation, EFSA should adopt a conclusion on whether fluazaindolizine can be expected to meet the approval criteria provided for in Article 4 of the Regulation, taking into consideration recital (10) of the Regulation. A final consultation on the conclusions arising from the peer review of the risk assessment took place with Member States via a written procedure in November‐December 2025 and in April 2026. This conclusion report summarises the outcome of the peer review of the risk assessment on the active substance and the formulation for representative uses evaluated on the basis of the representative uses of fluazaindolizine as a nematicide on cucurbits edible peel (cucumber, courgette) and carrot as proposed by the applicant. In accordance with Article 12(2) of Regulation (EC) No 1107/2009, risk mitigation options identified in the DAR and considered during the peer review, if any, are presented in the conclusion. Furthermore, this conclusion also addresses the requirement for an assessment by EFSA under Article 12 of Regulation (EC) No 396/2005, provided that the active substance will be approved under Regulation (EC) No 1107/2009 without restrictions affecting the residue assessment. In the event of a non‐approval of the active substance or an approval with restrictions that have an impact on the residue assessment, the MRL proposals, if any, from this conclusion might no longer be relevant and a new assessment under Article 12 of Regulation (EC) No 396/2005 will be required. A list of the relevant end points for the active substance and the formulation and the proposed MRLs is provided in Appendix B. In addition, the considerations as regards the cut‐off criteria for fluazaindolizine according to Annex II of Regulation (EC) No 1107/2009 are summarised in Appendix A. A key supporting document to this conclusion is the peer review report (EFSA, 2026), which is a compilation of the documentation developed to evaluate and address all issues raised in the peer review, from the initial commenting phase to the conclusion. The peer review report comprises the following documents, in which all views expressed during the course of the peer review, including minority views, where applicable, can be found: the comments received on the DAR;the reporting table (16 February 2024);the evaluation table (26 May 2026);the reports of the scientific consultation with Member State experts (where relevant);the comments received on the assessment of the additional information (where relevant);the comments received on the draft EFSA conclusion. the comments received on the DAR; the comments received on the DAR; the reporting table (16 February 2024); the reporting table (16 February 2024); the evaluation table (26 May 2026); the evaluation table (26 May 2026); the reports of the scientific consultation with Member State experts (where relevant); the reports of the scientific consultation with Member State experts (where relevant); the comments received on the assessment of the additional information (where relevant); the comments received on the assessment of the additional information (where relevant); the comments received on the draft EFSA conclusion. the comments received on the draft EFSA conclusion. Given the importance of the DAR, including its revisions (Malta, 2026), and the peer review report, both documents are considered as background documents to this conclusion and thus are made publicly available. It is recommended that this conclusion and its background documents would not be accepted to support any registration outside the EU for which the applicant has not demonstrated that it has regulatory access to the information on which this conclusion report is based. THE ACTIVE SUBSTANCE AND THE FORMULATION FOR REPRESENTATIVE USES Fluazaindolizine is the ISO common name for 8‐chloro‐N‐[(2‐chloro‐5‐methoxyphenyl)sulfonyl]‐6‐(trifluoromethyl)imidazo[1,2‐a]pyridine‐2‐carboxamide (IUPAC). 2 The formulation for representative uses for the evaluation is ‘Salibro’ (also referred to as ‘GF‐3880’), a suspension concentrate (SC) containing 500 g/L pure fluazaindolizine. The information on the active substance and the formulation for representative uses, including the co‐formulants in this formulation, was considered in the overall assessment during the peer review. None of the co‐formulants is an unacceptable co‐formulant listed in Annex III of Regulation (EC) No 1107/2009, 3 however a component of a co‐formulant is a component of a currently approved active substance, and a co‐formulant and a component of a co‐formulant are non‐approved active substances under Regulation (EC) 1107/2009 (not linked to safety concerns). At the reported concentrations, those co‐formulants are not expected to exert any pesticidal activity. Data gaps for the composition of a co‐formulant and some properties of other two co‐formulants were identified 4 (data gap, see Section 10). Details on the composition of the formulations cannot be reported in conclusions because of the provisions in Article 63(2)(d) of Regulation (EC) No 1107/2009, however this information was fully available and evaluated during the peer review. A proposal for classification of the formulation(s) according to Regulation (EC) 1272/2008 was provided by the applicant and assessed by the RMS (please see Volumes 3 CP of the Renewal Assessment Report (RAR)). The representative uses evaluated were greenhouse (permanent structure) application by drip irrigation for control of root knot nematodes Meloidogyne spp. on cucumber and courgette, and field in furrow soil application for control of root knot nematodes Meloidogyne spp. on carrots. Full details of the GAP can be found in the list of end points in Appendix B. Information was submitted to conclude that the use of fluazaindolizine according to the representative uses proposed at EU level results in a sufficient nematicidal efficacy against the target organisms, following the guidance document SANCO/10054/2013‐rev. 3 (European Commission, 2013). CONCLUSIONS OF THE EVALUATION General aspects The availability of mammalian toxicity data/information for the formulation for representative uses ‘Salibro’ was discussed at the Pesticides Peer Review Experts' Teleconference (TC) 148 (refer to Section 2). 5 Studies and/or information addressing acute toxicity were available. Concerning the co‐formulants contained in the formulation for representative uses, sufficient toxicological data were available for all components, but three (present in concentrations well below 10% in the final formulation). For these three co‐formulants, the experts considered that the available toxicological information did not sufficiently address the genotoxicity and repeated dose toxicity potential of ‘Salibro’ following short‐ and long‐term exposure, and that these components might be considered for further assessment (data gap, see Section 10). The collected information, including information from the existing uses other than plant protection products, under regulated EU frameworks [e.g. REACH, 6 food additive (Regulation (EC) 1333/2008 7 ), approved feed additive (Regulation (EC) No 1831/2003 8 ) and food contact material (Regulation (EU) 2011/10 9 )] did not highlight any concern. The availability of ecotoxicity data with the formulation for representative uses was discussed at the Pesticides Peer Review Experts' TC 150 (refer to Section 5). 10 The experts also discussed the data retrieval search and the available data for the individual components. Considering the reasoning agreed by the experts, no concerns were identified. The need for further ecotoxicity data should be reconsidered once the toxicology data are available. IDENTITY, PHYSICAL/CHEMICAL/TECHNICAL PROPERTIES AND METHODS OF ANALYSIS The following guidance documents were followed in the production of this conclusion: European Commission, 2000, 2010, 2019, 2021a. Specification based on batch analysis from pilot scale productions is proposed, however the proposal was made at a very late stage of the peer review process which prevented proper discussion and evaluation of the proposal by EFSA and other MSs. 11 The proposed minimum purity of the technical material is 961 g/kg. It was not demonstrated that unknown/unspecified impurities are not present in the current manufacturing batches (data gap, see Section 10). The batches used in the (eco) toxicological assessment support the proposed specification (See Sections 2 and 5). There is no FAO specification available for fluazaindolizine. It is noted that according to Regulation (EU) 283/2013, 12 information on the analytical profile of batches should be provided again once industrial scale production methods and procedures have stabilised. The main data regarding the identity of fluazaindolizine and its physical and chemical properties are given in Appendix B. Adequate methods are available for the generation of data required for the risk assessment. Methods of analysis are available for the determination of the active substance and impurities in the technical material and for determination of the active substance in the formulation for representative uses. Fluazaindolizine residues in food/feed of plant origin can be monitored by high‐performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) in all commodity groups with limit of quantifications (LOQ) of 0.01 mg/kg. Efficiency of the extraction procedure used in the method was not addressed for high acid commodities however a data gap was not set since this matrix is not covered by the representative uses. A multi‐residue quick, easy, cheap, effective, rugged and safe (QuEChERS) method for monitoring fluazaindolizine residues in food/feed of plant origin was also provided however extraction efficiency of the method was not demonstrated. Residues of fluazaindolizine in food of animal origin can be analysed by HPLC–MS/MS with LOQs 0.01 mg/kg. It is noted that the residue definition for monitoring for ruminants is open (see Section 3). QuEChERS method using HPLC–MS/MS for monitoring fluazaindolizine residues in honey with a LOQ of 0.01 mg/kg is available. Fluazaindolizine residues in soil and water (surface, drinking and groundwater) can be monitored by HPLC–MS/MS with LOQs 1.0 μg/kg and 0.1 μg/L, respectively. Residue definition for monitoring for groundwater is open pending assessment of IN‐VM862 (see Sections 2, 4 and 7), it is noted that a validated method for its monitoring in drinking/groundwater exists. Appropriate HPLC–MS/MS method exists for monitoring of fluazaindolizine residues in air with a LOQ 0.50 μg/m3. Residue definition for monitoring in air is open pending assessment of IN‐VM862 (see Sections 2, 4, 7 and 9.1). As a consequence, a monitoring method for the metabolite in air might be needed. HPLC–MS/MS method can be used for monitoring of fluazaindolizine in body fluids (blood and urine) with LOQs 0.01 mg/L. The method used for animal products could be used for monitoring of fluazaindolizine in body tissues. MAMMALIAN TOXICITY The toxicological profile of the active substance fluazaindolizine was discussed at the Pesticides Peer Review Experts' TC 148 (24–30 September 2024) and assessed based on the following guidance documents: European Commission (2003, 2012), EFSA (2022), EFSA PPR Panel (2012) and ECHA (2017). The proposed reference specification for the active substance and associated impurities is supported from the toxicological point of view. The analytical methods used in the toxicity studies are considered fit‐for‐purpose (see Section 1). Systemic bioavailability was estimated to be 51% after oral dosing. Fluazaindolizine widely distributes, reaching its highest concentrations in plasma, liver, kidneys and lungs. There is no evidence for accumulation. Excretion of fluazaindolizine occurs predominantly through the faeces and urine. Similar primary metabolic pathways mainly consisting of o‐demethylation, hydroxylation of the phenyl ring and hydrolysis of the amide bond are present in all species in vivo. The primary metabolite IN‐UHD20, resulting from hydroxylation of phenyl ring, is formed at up to 7.2% of the administered dose, whereas other metabolites are below 0.2%–5.2% of administered dose. Fluazaindolizine is more rapidly metabolised in human hepatocytes in vitro than in other species. Dog hepatocytes have the lowest rate. No unique human metabolite was detected. However, the results of the in vitro comparative metabolism (IVCM) study indicated a disproportionate production of the metabolite IN‐REG72 by human hepatocytes as compared to hepatocytes from other species. The residue definition for body fluids and tissues is fluazaindolizine. The ECHA Committee for Risk Assessment (ECHA RAC) proposed fluazaindolizine for harmonised classification as Acute Tox 4 via the oral route (ECHA, 2025). Fluazaindolizine has low acute toxicity when administered to rats via dermal or inhalation routes. In addition, fluazaindolizine is not considered a skin or eye irritant, nor does it act as a skin sensitiser. Based on its UV–vis absorption spectra, phototoxicity and photomutagenicity testing is required for fluazaindolizine. As regards hazard, fluazaindolizine was positive in an in vitro phototoxicity assay, and considered positive for photomutagenicity, since phototoxicity is used as a surrogate for photomutagenicity testing in the absence of an ad hoc methodology. As regards risk assessment, the lack of an agreed methodology to assess the risks associated to the exposure to phototoxic and/or photomutagenic pesticide active substances prevents any conclusion to be drawn on this aspect (data gap and an issue that could not be finalised (see Section 9.1)). In short‐ and long‐term oral toxicity studies, the main target organs of toxicity were the liver in dogs (the basis for STOT RE 2 proposed harmonised classification (ECHA, 2025)), the kidney/urinary tract in both rats and mice, and the gall bladder, jejunum and salivary glands in mice. Nonspecific effects such as reduced body weight gain were also observed 13 , 14 The relevant short‐term oral no observed adverse effect level (NOAEL) is 17.4 mg/kg bw per day (1‐year dog) based on liver effects at 35.8 mg/kg bw per day as also supported by the NOAEL of the dog 90‐day study. In a rat 2‐year oral study, the relevant long‐term NOAEL is 76.4 mg/kg bw per day, based on microscopic non‐neoplastic histopathological changes in the kidneys in both sexes observed at 240.8 mg/kg bw per day and related urinalysis effects. In a mouse 18‐month oral study, the relevant long‐term NOAEL is 141.7 mg/kg bw per day based on increased incidences of amyloidosis of multiple organs in both sexes observed at 435.6 mg/kg bw per day. There was no evidence of carcinogenicity either in rats or mice. Based on available genotoxicity studies fluazaindolizine is unlikely to be genotoxic. This is in line with the proposed harmonised classification by the ECHA RAC (ECHA, 2025). In reproductive toxicity studies in the rat, fertility and overall reproductive performance were not impaired. Accordingly, the relevant reproductive NOAEL was the highest dose tested of 265.10 mg/kg bw per day. The offspring NOAEL is 37.91 mg/kg bw per day based on kidney and bladder histopathological changes. The relevant parental NOAEL is 29.71 mg/kg bw per day, based on urinary tract effects. In the rat developmental toxicity study, both the relevant maternal and developmental NOAELs are 200 mg/kg bw per day, based on reduced body weight and food consumption in dams and reduced body weight in foetuses. In the rabbit, the NOAEL for maternal toxicity is 30 mg/kg bw per day based on abortion and moribundity secondary to body weight loss or decreased body weight gain and reduced food consumption. No developmental effects were seen in foetuses up to the highest dose tested of 120 mg/kg bw per day, i.e. rabbit developmental NOAEL. Fluazaindolizine did not show any potential for neurotoxicity in the acute and repeated neurotoxicity studies in rats. A systemic NOAEL of 125 mg/kg bw per day for reduced body weight and food consumption at ≥ 450 mg/kg bw was identified in the rat acute neurotoxicity study. There was no indication of immunotoxicity for the active substance in the available dataset in rats. The acceptable daily intake (ADI) is 0.17 mg/kg bw per day, on the basis of the NOAEL of 17.4 mg/kg bw for liver toxicity in the dog 1‐year study (as also supported by the 90‐day study in dogs) and a standard uncertainty factor of 100. The acute reference dose (ARfD) is 1.25 mg/kg bw based on the systemic NOAEL from the rat acute neurotoxicity study and an uncertainty factor of 100. The systemic acceptable operator exposure level (AOEL) is 0.09 mg/kg bw per day based on the NOAEL of 17.4 mg/kg bw per day in the 1‐year dog study (as also supported by the 90‐day study in dogs). A standard uncertainty factor of 100 and a correction of 51% for oral bioavailability were applied. The acute AOEL (AAOEL) is 0.64 mg/kg bw based on the systemic NOAEL of 125 mg/kg bw per day from the rat acute neurotoxicity study. A standard uncertainty factor of 100 and a correction of 51% for oral bioavailability were applied. Moreover, to account for the potential disproportionate formation of IN‐REG72 in humans, the experts agreed to also incorporate an assessment including an additional margin of 2 in the dietary and non‐dietary risk assessment for the active substance. 15 The outcome of these non‐dietary estimates for the representative uses of fluazaindolizine is presented in the paragraphs below. The non‐dietary exposure, including the dermal absorption data, of the active substance fluazaindolizine, was discussed. Based on an in vitro study with human skin conducted with the formulation for representative uses, ‘Salibro’, the dermal absorption values are 1.7% for the concentrate (SC 500 g/L) and 6.5% for the in‐use dilution (1 g/L). Appropriate pro‐rata corrections were applied for use on carrots, while default 50% dermal absorption was applied for drip irrigation. 16 For the proposed drip irrigation use in greenhouses (permanent), the experts concluded that for the operator only exposure during mixing/loading in a tank is relevant, for bystander and resident only exposure to vapours is relevant, while for workers the relevant exposure pathway is the soil‐borne residue (dermal and inhalatory exposure). The EFSA model 2022 was used to predict the exposure estimates. Operator exposure is predicted to remain below the (A)AOEL for an operator that wears standard workwear without any further personal protective equipment (PPE). Similarly, the predicted vapour exposure levels for residents and bystanders (both adults and children) are below the (A)AOEL without specific risk mitigation measure (considering the default buffer zone of 2–3 m). The predicted worker exposure levels were also below the AOEL without use of PPE. Detailed exposure estimates are provided in Appendix B. For the field use on carrots via in furrow spray application, experts concluded that operator, bystander and resident exposure should be estimated using the EFSA calculator 2022 for low crop vehicle mounted application, excluding the (re‐)entry into treated crops for bystanders, residents and workers. Worker exposure is not relevant for this type of application. The resulting operator exposure estimate is below the (A)AOEL, for an operator that wears workwear and no further PPE. Similarly, the predicted exposure levels for residents and bystanders (both adults and children, excluding the entry into treated crop) are lower than the (A)AOEL, without specific risk mitigation measure (considering the default buffer zone of 2–3 m). Detailed exposure estimates are provided in Appendix B. Genotoxicity and general toxicological data were submitted for some of the metabolites found as residues in crops or livestock and/or in groundwater. The genotoxicity and toxicological profile of these metabolites also relied on quantitative structure–activity relationship (QSAR) predictions, robust grouping (after identifying six lead compounds) and/or read across. Such approach was supported by physico‐chemical, structural/functional group/mechanistic/and/or ADME similarities and experimental data for at least one member of the proposed groups (see Table 1 for an overview of residue metabolites). 17 Overall, for none of the metabolites found as residues in plants and/or livestock (including processed commodities) triggering toxicological assessment for the representative uses under evaluation was a genotoxicity concern identified (see Appendix B and Table 1). For IN‐VM862, aneugenicity was not properly investigated (data gap and issue that could not be finalised regarding the groundwater relevance assessment, see Appendix D and Section 9.1). Concerning general toxicity, the parent's health based‐guidance values (HBGVs) are considered applicable to all the residue metabolites listed in Appendix D (except for IN‐VM862), based on repeated dose toxicity studies for some metabolites, robust grouping and read across, also taking into consideration target organ toxicity.12 The residue metabolites IN‐QEK31, IN‐F4106, and IN‐A5760 are also present in GW in concentrations above 0.75 μg/L (see Section 4 and Table 2 of Section 7) but are not relevant. 18 The concentration of IN‐VM862 in GW is above 0.75 μg/L and this metabolite is qualitatively and quantitatively different from the parent with respect to target organ toxicity (and Table 2 of Section 7)12. Thus, specific ADI was derived for IN‐VM862, that is 0.002 mg/kg bw per day based on the NOAEL of 2 mg IN‐VM862/kg bw per day in a rat 90‐day study and an overall UF of 1000 to also account for the sub‐chronic to chronic extrapolation and missing toxicological data. These HBGVs might be affected in the future, pending the outcome of the assessment of IN‐VM862 aneugenic potential (Appendix D). Moreover, it is noted that metabolite IN‐VM862 is volatile (see Section 4) and, accordingly, the exposure and risk to humans (such as workers and bystanders) should be assessed. However, data on the toxicity profile of IN‐VM82 by inhalation have not been provided (data gap leading to an issue that could not be finalised, see Section 9.1). Considering that fluazaindolizine contains the C‐CF3 group, trifluoroacetic acid (TFA) may be formed as a metabolite. The toxicity of the metabolite TFA was the subject of a notification falling under Article 56 of Regulation (EC) No 1107/2009 concerning information on potentially harmful or unacceptable effects. The notification concerned adverse developmental effects in rabbits after exposure to TFA observed in a new developmental toxicity study. HBGVs for consumer risk assessment have been peer reviewed previously by EFSA. An ADI of 0.05 mg/kg bw per day (expressed as sodium trifluoroacetate) was derived and an ARfD was deemed unnecessary (EFSA, 2017). It is noted that the derivation of reference values could be affected by the conclusion on aneugenicity, as outlined in the EFSA Scientific Committee guidance on aneugenicity assessment (EFSA Scientific Committee, 2021). In addition, a CLH proposal for reproductive toxicity category 1B has been sent to ECHA, 19 based on the aforementioned new developmental toxicity study in the REACh registration dossier for TFA. 20 Finally, it is also noted that EFSA received a mandate from the European Commission on the revision of the HBGVs on TFA 21 which is ongoing. RESIDUES The assessment in the residue section is based on the following guidance documents: OECD (2009, 2011), European Commission (2017) and JMPR (2004, 2007). Fluazaindolizine was discussed at the Expert consultation TC 151 and TC 162 taking place on 7–10 October 2024 and 11–12 February 2025, respectively. Metabolism in primary crops was investigated in fruits, pulses and oilseeds, roots and miscellaneous crops. Applications were made to soil, with an additional post‐emergence application to root crops. Qualitatively, the metabolism pattern was similar in all investigated crops. Fluazaindolizine contains the C‐CF3 group and TFA may be formed as a metabolite in plants. From the metabolic pattern and the identification rates the likelihood of the formation is limited. 22 TFA is known to be taken up from soil in rotational crops. Based on the extensive metabolism seen in metabolism studies and considering the results from the field trials, the most relevant residues for the risk assessment residue definition (RA‐RD) are fluazaindolizine, IN‐A5760, IN‐F4106, IN‐QEK31, IN‐QZY47, IN‐TMQ01, IN‐UJV12, IN‐UNS90 and IN‐REG72 in their free and conjugated forms. To avoid double counting of residues due to cleavage of the parent molecule, with all compounds sharing the same tox reference values (see Appendix D), the risk assessment residue definition can be implemented by taking the maximum of the sum of compounds containing the phenyl ring after hydrolysis: IN‐A5760, IN‐F4106, IN‐QZY47, IN‐TMQ01, IN‐UJV12 and IN‐UNS90, expressed as fluazaindolizine (RA‐RD a) or compounds containing the imidazopyridine ring after hydrolysis: IN‐QEK31, expressed as fluazaindolizine (RA‐RD b). For the enforcement residue definition fluazaindolizine is proposed as it is a unique marker. Conversion factors could not be proposed from the current residue dataset since the levels of fluazaindolizine in the field trials were ≤ 0.01mg/kg. A confined rotational crop metabolism study was conducted in cereals, root and leafy crops using the same radiolabelling as primary crops (phenyl and imidazopyridine ring) and covering all plant‐back intervals (PBIs) at approx. 2.5 N rate compared with the maximum annual rate. Fluazaindolizine, IN‐QEK31, IN‐REG72, IN‐F4106, IN‐A5760 are persistent compounds in soil (see Section 4). Although the application rate does not cover the accumulated predicted environmental concentration (PEC) of all persistent compounds, the metabolic pattern is not expected to differ but might be quantitatively affected. For rotational crops, the C‐CF3 moiety was also not investigated, and this might be required pending the outcome of the additional data requested in environmental fate (see Section 4) on the possible formation of TFA in soil. Thus, the residue definitions for rotational crops are provisionally proposed as the same as for primary crops since the metabolic pattern is similar. Sufficient GAP‐compliant trials in carrots and cucumbers/courgettes were submitted and analysed for all RA‐RD compounds. While most of the compounds were covered by appropriate storage stability data, for IN‐UJV12 additional storage stability data is required to support field trials in carrots (data gap, see Section 10). Twelve rotational crop field trials were conducted on various crops in Europe at application rates ranging from 1.25 to 2.5 kg a.s./ha (see Appendix B). However, it is not demonstrated that these rates cover the accumulated PEC values of the persistent soil metabolites (data gap see also Sections 4 and 9.1). Storage stability data for IN‐UJV12 does not cover most of the trials (with few exceptions), while for the other relevant metabolites, several trials are also not covered by valid storage stability. Therefore, considering the issues reported above on PEC coverage and storage stability, further evaluation of these field trials is needed (data gap, see Section 10, see also data gap on rotational crops trials, Section 9.1). High temperature hydrolysis (HTH) studies on fluazaindolizine demonstrated no degradation under conditions of baking/boiling/pasteurisation and sterilisation. However, no HTH studies were available for the metabolites included in the RA‐RD, which are triggered by residues above 0.01 mg/kg (data gap, see Section 10). Due to data gaps for reliable residue field trials with rotated crops (see above), a final dietary burden calculation is not feasible (data gap, see Section 9.1). In the revised DAR (Malta, 2026) RMS has presented separate dietary burden calculations for fluazaindolizine and all seven plant metabolites included in the residue definitions. These calculations are considered indicative because of data gaps (see above) and because of not fully supported assumptions (see explanation in Evaluation table Section 3, open point 3.22 (EFSA, 2026)). The outcome is that animal studies for all species with fluazaindolizine and all metabolites are triggered. Livestock metabolism studies were presented with fluazaindolizine and IN‐QEK‐31 (bearing the [Imidazo[1,2‐a]pyridine‐2‐14C] moiety) and IN‐QZY47 (bearing the phenyl moiety) for ruminants and poultry and in addition with IN‐TMQ01 for ruminants. Despite some shortcomings (see data gap, Section 10) they sufficiently depict the qualitative metabolic pattern in livestock which is similar in poultry and ruminants. In both species fluazaindolizine and IN‐QEK‐31 are hardly metabolised whereas IN‐QZY47 is further metabolised to mainly IN‐F4106 and IN‐A5760. Due to a relative low transfer of the residues to poultry tissues and eggs, the residue definitions for risk assessment and enforcement in poultry is proposed as fluazaindolizine. The indicative calculations revealed a considerable higher dietary burden for ruminants in contrast to poultry which together with the higher residue levels in tissues and milk underlining the need for a more precise dietary burden calculation to estimate the carry‐over of residues to ruminants and derive a robust residue definition for ruminants. From the current data a provisional risk assessment residue definition for ruminants can be proposed as fluazaindolizine and metabolites containing the phenyl ring: IN‐A5760 (free and conjugated), IN‐F4106, IN‐TMQ01 and IN‐UNS90; metabolites containing the imidazopyridine ring: IN‐QEK31. Based on a robust dietary burden calculation for all feed metabolites with valid residue data from rotational crop field trials (see data gaps above), transfer factors should be derived using existing metabolism studies with fluazaindolizine and metabolites, and the feeding study with fluazaindolizine to consider the relevance of feed metabolites for which animal studies were not available (data gap, see Section 9.1). Fish metabolism studies were not triggered by the primary crops since they are not fish feed items; pending the additional data on rotational crops, studies on fish may be required. As regards the level of residues in bee products for human consumptions, five trials were submitted showing the residue levels were < 0.01mg/kg (see Appendix B). A provisional consumer risk assessment was conducted for primary crops and honey only with inputs values from the field trials, the derived HBGVs by using EFSA Primo 3.1 model. The calculated international estimated daily intake (IEDI) accounted 0.1% of the ADI (DK, child) and the international estimated short‐term intake (IESTI) is 0.4% of the ARfD. The consumer risk assessment could not be finalised in view of the data gaps identified in rotational crops and animal commodities. As regards the consumer exposure via drinking water, an assessment was triggered for the metabolites IN‐QEK31, IN‐F4106, IN‐A5760 and IN‐VM862. The consumer exposure estimates for groundwater metabolites were based on the default assumptions laid down in the WHO Guidelines (WHO, 2017) for drinking water quality for (a) a 60‐kg adult drinking 2 L of water per day, (b) a 10‐kg child drinking 1 L of water per day and (c) a 5‐kg bottle‐fed infant drinking 0.75 L of water per day, and the maximum concentrations of the relevant metabolites. Three exposure calculations were conducted considering the HBGVs (see Section 2), the expression of residues in the plant RA‐RD and the maximum of residues found: (1) IN‐F4106 and IN‐A5760; (2) IN‐QEK31 and (3) IN‐VM862. Exposure to IN‐F4106 and IN‐A5760 as groundwater metabolites accounted for 0.2% of the ADI for adults, 0.5% for children and 0.7% for infants. Exposure to IN‐QEK31 as groundwater metabolite accounted for 0.1% of the ADI for adults, 0.3% for children and 0.5% for infants. IN‐VM862 as groundwater metabolite accounted 12.1% ADI for adults, 36.2% for children and 54.3% for infants and is for IN‐VM862 only indicative due to data gaps (data gap, see Section 9.1). The consumer risk assessment from the consumption of drinking water could also not be finalised considering the lack of appropriate information to address the effect of water treatment processes on the nature of residues of the active substance and its identified metabolites, that might be present in surface water or groundwater, when surface water and/or groundwater are abstracted for the production of drinking water (see Sections 4 and 9.1). ENVIRONMENTAL FATE AND BEHAVIOUR Fluazaindolizine was discussed at the Pesticides Peer Review Meeting Teleconference (TC) 149 in 23–27 September 2024. The rates of dissipation and degradation in the environmental matrices investigated were estimated using FOCUS (2006) kinetics guidance. In soil laboratory incubations under aerobic conditions in the dark, fluazaindolizine exhibited low to high persistence and it was concluded that the degradation rate of fluazaindolizine was pH dependent. 23 Fluazaindolizine formed the major metabolites (> 10% applied radioactivity (AR)) such as IN‐A5760 (max. 16.1% AR) which exhibited moderate to very high persistence, IN‐F4106 (max. 86% AR) which exhibited medium to very high persistence, IN‐QEK31 (max. 79% AR) which exhibited moderate to high persistence, IN‐REG72 (max. 7.5% AR) which exhibited low to high persistence and metabolite IN‐VM862 (max. 21% AR) which exhibited very high persistence. However, it should be noted that metabolite IN‐VM862 is highly volatile, and then the rate of degradation in soil was calculated by summing the amounts in both the soil‐extracted and volatilised compartments, which is considered the worst‐case for soil exposure. 24 The presence of C‐CF3 group in fluazaindolizine indicates that TFA may be formed during the degradation of the active substance in environmental compartments. However, this potential degradation pathway was not investigated, therefore an issue that could not be finalised and a data gap were identified 25 (see Section 9.1). Mineralisation of the phenyl, imidazo‐pyridine and imidazo ring radiolabels to carbon dioxide accounted for 0.1%–13.1% AR after 100 days. The formation of unextractable residues (not extracted by e.g. sodium hydroxide or acetonitrile/water and/or methanol and/or methanol/water) for these radiolabels accounted for 4.5%–34% AR after 100 days. In anaerobic soil incubations, fluazaindolizine degraded more slowly than under aerobic conditions with the route of degradation being the same as in the aerobic investigations, except for the formation of metabolites IN‐REG72 and IN‐VM862. Under experimental soil photolysis conditions, fluazaindolizine was transformed to the major metabolite IN‐F4106 (max. 24% AR). A data gap was identified for adsorption studies on fluazaindolizine and IN‐VM862 (see Section 10 for fluazaindolizine and 9.1 for IN‐VM862) and its metabolites IN‐F4106, IN‐A5760, IN‐REG72, IN‐QEK31 (one additional soil) (see Section 10). These studies encountered systematic errors due to high levels of non‐extractable radioactivity (OECD 106 evaluators checklist, EFSA, 2017). Environmental exposure modelling results can be retained with some uncertainty, since adsorption parameters were assessed indirectly and a significant proportion of radioactivity was unextracted. Based on this, fluazaindolizine exhibited high to medium mobility in soil. Metabolites IN‐QEK31 and IN‐A5760 exhibited very high to high mobility soil mobility, metabolites IN‐REG72 and IN‐VM862 exhibited high to medium soil mobility and metabolite IN‐F4106 exhibited high soil mobility. No pH dependency was identified for the soil adsorption of fluazaindolizine and its metabolites. In satisfactory field dissipation studies carried out at one site each in France, Greece, Italy, Spain, Florida and Canada, and four sites in California (spray application to the soil surface on bare soil plots), fluazaindolizine exhibited low to high persistence. Sample analyses were carried out for metabolites IN‐QEK31, IN‐F4106, IN‐A5760, IN‐REG72, IN‐VM862 in addition to fluazaindolizine. TFA was not an analyte. Field study DT50 values were accepted as being reasonable estimates of degradation and were normalised to FOCUS reference conditions (20°C and pF2 soil moisture) using the time step normalisation procedure in accordance with FOCUS (2006) kinetics guidance. For higher tier modelling, the field data endpoints were combined with lab values to derive modelling endpoints for fluazaindolizine and metabolites IN‐QEK31, IN‐A5760 and IN‐REG72 (EFSA, 2014b). In laboratory incubations in dark aerobic natural sediment water systems, fluazaindolizine exhibited moderate persistence, forming the major metabolites IN‐REG72 (max. 52% AR in water and max. 41% AR in sediment, exhibiting high persistence), IN‐QEK31 (max. 5.7% AR in water and max. 4.3% AR in sediment) and IN‐A5760 (max. 6% AR in water and max. 4.4% AR in sediment). The unextractable sediment fraction (not extracted by e.g. sodium hydroxide or acetonitrile) was a limited sink for the phenyl and imidazo‐pyridine ring 14C radiolabels, accounting for 5.2%–11% AR at study end (100 days). Mineralisation of these radiolabels accounted for 0.45%–1.7% AR at the end of the study. The rate of decline of fluazaindolizine in a laboratory aqueous photolysis experiment was high relative to that occurred in the aerobic sediment water incubations. Chromatographically resolved components accounting for > 10% AR were IN‐F4106 (max. 13.1% AR) and IN‐UGA22 (max. 23.9% AR). Two additional aqueous photolysis metabolites were detected but not characterised resulting in unknown chromatogram peaks with retention time 2.3 and 31.5 min (data gap, see Section 9.1). 26 The necessary surface water and sediment exposure assessments (PEC calculations) were carried out for the metabolites IN‐F4106, IN‐QEK31, IN‐REG72, IN‐VM862, IN‐A5760 and IN‐UGA22 using the FOCUS (FOCUS, 2001) step 1 and step 2 approach (version 3.2 of the Steps 1–2 in FOCUS calculator). For the active substance fluazaindolizine and metabolites IN‐REG72 and IN‐A5760 appropriate Step 3 (FOCUS, 2001) calculations were available 27 for the representative uses in field for carrots and greenhouses (permanent, considering only D6 scenario) for cucumbers. Time dependent sorption behaviour was demonstrated during the soil incubation laboratory experiments for fluazaindolizine and its metabolite IN‐QEK31. 28 Aged sorption parameters were derived using PEARLNEQ v5.1. For representative field uses, the lower and higher tier considering aged sorption (European Commission, 2021b) groundwater exposure assessments were appropriately carried out using FOCUS (European Commission, 2014) scenarios and the models PEARL 4.4.4, PELMO 5.5.3 and MACRO 5.5.4. 29 The groundwater exposure assessment was completed considering acidic and alkaline soil condition due to the pH dependency degradation for fluazaindolizine. Higher tier groundwater exposure assessments of representative use in field on carrots were performed in acidic and alkaline soil conditions. For fluazaindolizine, the 80th percentile annual average concentrations moving below 1m depth were predicted to remain below the parametric drinking water limit of 0.1 μg/L. In alkaline and acidic soil conditions, for the metabolites IN‐QEK31, IN‐F4106, IN‐VM862 and IN‐A5760, the 80th percentile annual average concentrations moving below 1m depth were predicted to be above the parametric drinking water limit of 0.1 μg/L in six out of six FOCUS groundwater scenarios, exceeding also 0.75 μg/L. For metabolite IN‐REG72, the 80th percentile annual average concentrations moving below 1m depth were predicted to be below the parametric drinking water limit of 0.1 μg/L in all FOCUS groundwater scenarios. In general, predicted groundwater concentration in alkaline soil conditions resulted to be slightly higher than acidic soil conditions. For the representative uses in greenhouses (permanent) on cucumbers, calculations were available for fluazaindolizine and its soil metabolites using the Pistoia scenario (EFSA, 2014a). In alkaline and acidic soil condition the 80th percentile annual average concentrations moving below 1m depth were predicted to be above the parametric drinking water limit of 0.1 μg/L for metabolites IN‐QEK31, IN‐F4106, IN‐VM862 and IN‐A5760. It should be noted that the scenario definition used was an EU guidance agreed example scenario reflecting Italian conditions for greenhouses (permanent). However, it also needs to be noted that it may not be representative for the range of these structure types present in all EU territories. In addition, a groundwater exposure assessment with standard FOCUS weather is also available, however this would represent an open field application. Based on the information available in the mammalian toxicity section, metabolites IN‐QEK31, IN‐F4106 and IN‐A5760 are considered to be non‐relevant groundwater metabolites regarding human health, while the groundwater relevance assessment for metabolite IN‐VM862 remains open (see Section 2) leading to the groundwater assessment of IN‐VM862 being an issue that could not be finalised (see Section 9.1). The applicant did not fully address the effect of water treatment processes on the nature of the residues that might be present in surface water and groundwater, when surface water or groundwater are abstracted for drinking water. In particular, the degradation of fluazaindolizine and its potential contribution to the formation of degradation products including TFA in drinking water processes as was not addressed. This has led to the identification of a data gap and results in the consumer risk assessment not being finalised (see Sections 3 and 9.1). Fluazaindolizine that will form aerosols at the time of spraying in furrow on carrots and volatile metabolite IN‐VM862, both have the potential for long‐range atmospheric transport as their half lives in the upper atmosphere are estimated to be longer than 2 days. However, these compounds have logPow below 3 so they are not persistent organic pollutants (POP) as they do not have indications for bioaccumulation. A PEC in air is not available for IN‐VM862 (data gap) which in combination with missing inhalation mammalian toxicity information or any other human non‐dietary exposure estimates being available for it (see Section 2), leads to an issue that could not be finalised for a uniform principles authorisation criterion, see Section 9.1. The PEC in soil, surface water, sediment and groundwater covering the representative uses assessed can be found in Appendix B of this conclusion. A key to the wording used to describe the persistence and mobility of the compounds assessed can be found in Appendix C of this conclusion. ECOTOXICOLOGY The risk assessment was based on the following documents: European Commission (2002), SETAC (2001), EFSA (2009, 2013) and EFSA PPR Panel (2013). Aspects of the ecotoxicology risk assessment were discussed during the Pesticides Peer Review Experts' Teleconference 150 (30 September–7 October 2024). The available data was sufficient to confirm the compliance of the batches used in the ecotoxicity studies with the reference specification. Considering that fluazaindolizine contains the C‐CF3 group, TFA has the potential to be present in soil, water and rotational crops (see Sections 3 and 4). With the available information it is not known whether TFA will be listed in the definition for residues that require a risk assessment. Consequently, although the ecotoxicological risk assessment for fluazaindolizine and the identified metabolites could be finalised (as presented in the paragraphs below), such assessment may need to be reconsidered pending the outcome of the data gaps and, accordingly, the decision on a conclusive residue definition for risk assessment (see Sections 3, 4 and 9.1). Acute and long‐term studies on birds and mammals were available for fluazaindolizine. Additionally, acute studies using the formulation for the representative uses were submitted for both groups of terrestrial vertebrates. The relevant ecotoxicological NOAEL for wild mammals was discussed during the Pesticides Peer Review Experts' Teleconference 150. 30 A low acute and long‐term risk to birds and wild mammals was concluded for all representative uses of fluazaindolizine at screening step. An assessment of the risk to birds and wild mammals from secondary poisoning was not required in consideration of the relatively low lipophilicity of fluazaindolizine and its relevant plant metabolites. For the consumption of contaminated water from water puddles, a low acute and long‐term risk is concluded for both birds and wild mammals. The risk assessment for the relevant plant metabolites IN‐QEK31, IN‐A5760, IN‐QZY47 and IN‐TMQ01 was carried out assuming equal toxicity to fluazaindolizine. A low risk is concluded for relevant plant metabolites for both birds and wild mammals. A low risk could be concluded even when these metabolites are considered 10‐times more toxic than the parent compound. Aquatic acute and chronic toxicity data (fish, aquatic invertebrates, sediment dwelling organisms, algae and aquatic plants) were available with the active substance fluazaindolizine. Furthermore, toxicity data with the formulation for representative use (Fluazaindolizine 500 g/L SC) was available for fish (acute), aquatic invertebrates (acute), algae and aquatic plants. The chronic endpoint for sheepshead minnow 31 and the pH ranges in the aquatic studies 32 were discussed at the experts' meeting. It was agreed that fluazaindolizine being a weak acid, the pH might have some impact on its toxicity, however this uncertainty is not expected to impact the outcome of the risk assessment. The aquatic exposure assessment identified six pertinent metabolites which need a risk assessment in surface water (IN‐F4106, IN‐QEK31, IN‐REG72, IN‐VM862, IN‐A5760, IN‐UGA22) and two pertinent metabolites which need a risk assessment in sediment (IN‐REG72, IN‐A5760). For the metabolites IN‐F4106 and IN‐QEK31 toxicity data were available for fish (acute), aquatic invertebrates (acute and chronic) and algae. For the metabolite IN‐VM862, toxicity data were available for fish (acute), aquatic invertebrates (acute) and algae, whereas for the metabolite IN‐REG72, toxicity data were available for aquatic invertebrates (acute) and algae. Data were not available for the metabolites IN‐A5760 and IN‐UGA22. Following the data gap in Section 4 regarding the two unidentified peaks, further data might be required when additional information is available (see Sections 4 and 9.1). The available aquatic risk assessment demonstrated a low acute and chronic risk to fish, aquatic invertebrates, algae and higher plants from fluazaindolizine at Focus step 2 or 3. A low chronic risk to sediment dwelling organisms was demonstrated from Fluazaindolizine at Focus step 2. The approach for the metabolite IN‐REG72 was discussed at the experts' meeting. 33 It was agreed that, as there is uncertainty on the loss of the toxicity for non‐target organisms, such as fish and sediment‐dwellers, the risk assessment should be carried out considering the metabolite as 10‐times more toxic than the parent. The available risk assessment for metabolites IN‐F4106, IN‐QEK31, IN‐VM862, IN‐REG72, 34 IN‐A5760, IN‐UGA22 indicated a low risk to aquatic organisms. The available risk assessment for metabolites IN‐REG72 and IN‐A5760 indicated a low risk to sediment dwelling organisms. Acute oral and contact toxicity studies were available for honey bees with the active substance, the formulation for the representative uses, and two of the plant‐relevant metabolites (IN‐F4106 and IN‐QEK31). Chronic studies with adult bees and brood were also available for the active substance and the same two metabolites, but not for the formulation. Additionally, two semi‐field studies (according to OECD 75 test guidance) were also available with the formulation. Acute oral and contact toxicity data for the active substance, the formulation and the metabolites IN‐F4106 and IN‐QEK31 were also available for bumble bees. A risk assessment according to European Commission (2002) was available, based on which low acute risk from oral and contact exposure to honey bees was concluded for all representative uses. In addition, a risk assessment following EFSA (2013) guidance also was available, reaching the same conclusion. Following EFSA (2013) guidance, a high chronic risk to adult bees was indicated at Tier‐1 for both field uses, carrots and cucurbit, through exposure to flowering weeds, treated crop and rotational crop. Additionally, for the field use in carrots, a high chronic risk to bee larvae was also indicated from exposure to flowering weeds. The risk assessment for metabolites was based on the maximum application rate of 750 g a.s./ha, considered protective across all uses. For the metabolites IN‐VM862 and IN‐A5760, no specific toxicity studies were available. However, since their chemical structures closely resemble those of the metabolites from which they form (these being IN‐F4106 and IN‐QEK31, respectively), existing toxicity data for these metabolites were used with a safety factor of 10. Specifically, endpoints from IN‐QEK31 and endpoints from IN‐F4106, divided by 10, were used for IN‐VM862 and IN‐A5760 respectively. This approach was discussed and agreed at the Pesticides Peer Review Experts' Teleconference 150. 35 Based on this assessment, a low risk could not be demonstrated for IN‐VM862 (treated and next crop). In contrast, IN‐QEK31, IN‐F4106 and IN‐A5760 were considered to pose a low risk to bees. The two available semi‐field studies were discussed during the Pesticides Peer Review Experts' Teleconference 150 (October 2024). 36 It was agreed that these studies were not sufficient to support a quantitative risk assessment. However, the results showed no apparent adverse effects on honey bee colonies and indicated that no residues of fluazaindolizine or relevant metabolites are detected at or above the limit of quantification (0.005 mg/kg) in any of the treated nectar and pollen samples, following representative application methods. Therefore, considering that: the qualitative indications from the toxicity from the semi‐field studies show no apparent adverse effects on honey bees colonies,high exposure was not expected with the proposed application methods, which was confirmed by the results from the residues from the semi‐field studies andno residues of fluazaindolizine and relevant metabolites were identified, the qualitative indications from the toxicity from the semi‐field studies show no apparent adverse effects on honey bees colonies, the qualitative indications from the toxicity from the semi‐field studies show no apparent adverse effects on honey bees colonies, high exposure was not expected with the proposed application methods, which was confirmed by the results from the residues from the semi‐field studies and high exposure was not expected with the proposed application methods, which was confirmed by the results from the residues from the semi‐field studies and no residues of fluazaindolizine and relevant metabolites were identified, no residues of fluazaindolizine and relevant metabolites were identified, an overall low chronic risk for adult and larvae (for both the parent and the metabolites) could be concluded based on a weight‐of‐evidence approach. Low acute risk was identified for bumble bees in any scenario. No data were submitted to perform a risk assessment for solitary bees or to characterise chronic risk to bumble bees. The toxicity to non‐target arthropods other than bees was investigated with the formulation for representative uses. A first‐tier risk assessment was done with the two indicator species: Typhlodromus pyri and Aphidius rhopalosiphim. Extended laboratory studies were carried out with two additional species: Aleochara bilineata and Pardosa spec. wolf spider. The results of the first‐ and extended laboratory studies with the formulation demonstrated a low in‐field and off‐field risk to non‐target arthropods. Appropriate laboratory chronic toxicity studies with the fluazaindolizine and the formulation for representative uses were available for earthworms (Eisenia fetida), other soil macro‐organisms (the Collembola Folsomia candida and the soil predatory mite Hypoaspis aculeifer), and soil microorganisms. The selection of the most appropriate endpoint for E. fetida was discussed during the Pesticides Peer Review Experts' Teleconference 150. 37 Based on the outcome the risk assessment, a low risk to all soil macro‐organisms and soil microorganisms was concluded for all representative uses of fluazaindolizine. Toxicity data were available for the relevant soil metabolites of fluazaindolizine IN‐F4106, IN‐QEK31, IN‐REG72, IN‐VM862, IN‐A5760 for E. fetida, H. aculeifer, F. candida and soil microorganisms. A low risk is concluded for the relevant soil metabolites for earthworms, other soil macro‐organisms and soil microorganisms. A low risk to organisms involved in biological methods for sewage treatment was concluded for all representative uses. For the assessment of non‐target terrestrial plants, suitable toxicity data investigating the effects of exposure to the active substance and the formulation for representative uses were available on seedling emergence and vegetation and vigour. On the basis of the available data and risk assessment, a low risk to non‐target terrestrial plants was concluded for all representative uses. ENDOCRINE DISRUPTION PROPERTIES The available studies for the ED assessment of both humans and non‐target organisms, their findings and related weight‐of‐evidence were discussed at the Peer Review Experts' meeting TC 147 in September 2024. With regard to the assessment of the endocrine disruption (ED) potential of fluazaindolizine for humans according to the ECHA/EFSA guidance (ECHA/EFSA, 2018), in determining whether fluazaindolizine interacts with the oestrogen, androgen and steroidogenesis (EAS) and thyroid (T) mediated pathways, the number and type of effects induced; and the magnitude and pattern of responses observed across studies were considered. Additionally, the conditions under which effects occur were considered, in particular, whether or not endocrine‐related responses occurred at dose(s) that also resulted in overt toxicity. The assessment is therefore providing a weight‐of‐evidence analysis of the potential interaction of fluazaindolizine with the EAS and T signalling pathways using the available evidence in the dataset. With regard to T modality, the data set was considered complete, and a pattern of T‐mediated adversity was not identified. For the EAS‐modalities, the dataset was considered complete, and a pattern of EAS‐mediated adversity was not observed. Therefore, based on the available and sufficient dataset, it was concluded that the ED criteria are not met for the ETAS modalities for humans (Scenario 1a of the ECHA/EFSA (2018) ED Guidance). The outcome of the assessment reported above for humans also applies to wild mammals as non‐target organisms. For non‐target organisms other than mammals, an Amphibian Metamorphosis Assay and a Fish Short‐Term Reproduction Assay were available to sufficiently investigate the endocrine activity through the T and EAS‐modalities, respectively. The studies were both valid and did not show any evidence of endocrine activity or adversity. 38 According to point 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605, it can be concluded that fluazaindolizine is not an endocrine disruptor. OVERVIEW OF THE RISK ASSESSMENT OF COMPOUNDS LISTED IN RESIDUE DEFINITIONS The content of the following tables is provisional pending submission of satisfactory information to demonstrate that TFA is not formed as a degradation product of fluazaindolizine in soil, and consequently to exclude the potential for its leaching into groundwater or running of or being drained into or formed in natural surface water systems (see further details in Section 4) (Tables 1, 2, 3, 4). TABLE 1Soil.Compound (name and/or code)Ecotoxicology Fluazaindolizine Low IN‐F4106 Low IN‐QEK31 Low IN‐REG72 Low IN‐VM862 Low IN‐A5760 Low Soil. TABLE 2Groundwater. a Compound (name and/or code)> 0.1 μg/L at 1 m depth for the representative uses b Biological (pesticidal) activity/relevanceHazard identifiedConsumer RA triggeredHuman health relevanceStep 2Step 3aSteps 3b and 3cSteps 4 and 5 Fluazaindolizine No (Field and greenhouses (permanent) representative uses)Yes––Yes IN‐REG72 No (Field and greenhouses (permanent) representative uses) Not triggered Not triggered No Not triggered IN‐QEK31 Yes, 6 out of 6 FOCUS Scenarios (5.738 μg/L)c (Field use) Yes, (1 out of 1) Pistoia Scenario (EFSA, 2014a) (1.029 μg/L) d (greenhouses (permanent)) No No Unlikely to be genotoxic Parent's ADI applies Yes Consumer maximum intake 0.5% of the ADI (infant) No for the representative uses assessed IN‐F4106 Yes, 6 out of 6 FOCUS Scenarios (5.272 μg/L)c (Field use) Yes, (1 out of 1) Pistoia Scenario (EFSA, 2014a) (1.965 μg/L) c (greenhouses(permanent)) No No Unlikely to be genotoxic Parent's ADI applies Yes Consumer maximum intake for the sum of IN‐F4106 and IN‐A5760 0.7% of the ADI (infant) No for the representative uses assessed IN‐VM862 Yes, 6 out of 6 FOCUS Scenarios (6.795 μg/L)c (Field use) Yes, 1 out of 1 Pistoia Scenario (EFSA, 2014a) (2.725 μg/L)d (greenhouses (permanent)) No Open Data gap for aneugenicity ADI 0.002 mg/kg bw per day (rat 90‐d NOAEL, UF 1000) Open Indicative consumer maximum intake 54% of the ADI (infant) Data gap IN‐A5760 Yes, 6 out of 6 FOCUS Scenarios (1.823 μg/L)c (Field use) Yes, 1 out of 1 Pistoia Scenario (EFSA, 2014a) (0.591 μg/L) c (greenhouses (permanent)) No No Unlikely to be genotoxic Parent's ADI applies Yes Consumer maximum intake for the sum of IN‐F4106 and IN‐A5760 0.7% of the ADI (infant) No for the representative uses assessed a Assessment according to European Commission guidance of the relevance of groundwater metabolites (2003). b FOCUS scenarios or relevant lysimeter. Ranges indicated for FOCUS scenarios include the result from the model giving the highest concentration at each scenario, as needed to comply with European Commission (2014) guidance. c Alkaline soil conditions. d Acidic soil conditions. Groundwater. a No (Field and greenhouses (permanent) representative uses) Not triggered Not triggered No Not triggered Yes, 6 out of 6 FOCUS Scenarios (5.738 μg/L)c (Field use) Yes, (1 out of 1) Pistoia Scenario (EFSA, 2014a) (1.029 μg/L) d (greenhouses (permanent)) No Unlikely to be genotoxic Parent's ADI applies Yes Consumer maximum intake 0.5% of the ADI (infant) Yes, 6 out of 6 FOCUS Scenarios (5.272 μg/L)c (Field use) Yes, (1 out of 1) Pistoia Scenario (EFSA, 2014a) (1.965 μg/L) c (greenhouses(permanent)) No Unlikely to be genotoxic Parent's ADI applies Yes Consumer maximum intake for the sum of IN‐F4106 and IN‐A5760 0.7% of the ADI (infant) Yes, 6 out of 6 FOCUS Scenarios (6.795 μg/L)c (Field use) Yes, 1 out of 1 Pistoia Scenario (EFSA, 2014a) (2.725 μg/L)d (greenhouses (permanent)) Open Data gap for aneugenicity ADI 0.002 mg/kg bw per day (rat 90‐d NOAEL, UF 1000) Open Indicative consumer maximum intake 54% of the ADI (infant) Yes, 6 out of 6 FOCUS Scenarios (1.823 μg/L)c (Field use) Yes, 1 out of 1 Pistoia Scenario (EFSA, 2014a) (0.591 μg/L) c (greenhouses (permanent)) No Unlikely to be genotoxic Parent's ADI applies Yes Consumer maximum intake for the sum of IN‐F4106 and IN‐A5760 0.7% of the ADI (infant) Assessment according to European Commission guidance of the relevance of groundwater metabolites (2003). FOCUS scenarios or relevant lysimeter. Ranges indicated for FOCUS scenarios include the result from the model giving the highest concentration at each scenario, as needed to comply with European Commission (2014) guidance. Alkaline soil conditions. Acidic soil conditions. TABLE 3Surface water and sediment. a Compound (name and/or code)EcotoxicologyFluazaindolizineLowIN‐F4106LowIN‐QEK31LowIN‐REG72LowIN‐VM862LowIN‐A5760LowIN‐UGA22Low a Provisional also due to the data gap for the two unknown metabolites reported in the photolysis study. Surface water and sediment. a Provisional also due to the data gap for the two unknown metabolites reported in the photolysis study. TABLE 4Air.Compound (name and/or code)ToxicologyFluazaindolizineRat LC50 inhalation > 5.3 mg/L air/4h (nose‐only exposure)IN‐VM862Data gap Air. PARTICULAR CONDITIONS PROPOSED TO BE TAKEN INTO ACCOUNT BY RISK MANAGERS Risk mitigation measures (RMMs) identified following consideration of Member State (MS) and/or applicant's proposal(s) during the peer review, if any, are presented in this section. These measures applicable for human health and/or the environment leading to a reduction of exposure levels of operators, workers, bystanders/residents, environmental compartments and/or non‐target organisms for the representative uses are listed below. The list may also cover any RMMs as appropriate, leading to an acceptable level of risks for the respective non‐target organisms. It is noted that final decisions on the need of RMMs to ensure the safe use of the plant protection product containing the concerned active substance will be taken by risk managers during the decision‐making phase. Consideration of the validity and appropriateness of the RMMs remains the responsibility of MSs at product authorisation, taking into account their specific agricultural, plant health and environmental conditions at national level. No particular conditions are proposed for the representative uses evaluated. CONCERNS AND RELATED DATA GAPS Issues that could not be finalised An issue is listed as ‘could not be finalised’ if there is not enough information available to perform an assessment, even at the lowest tier level, for one or more of the representative uses in line with the uniform principles in accordance with Article 29(6) of Regulation (EC) No 1107/2009 and as set out in Commission Regulation (EU) No 546/2011 39 and if the issue is of such importance that it could, when finalised, become a concern (which would also be listed as a critical area of concern if it is of relevance to all representative uses). An issue is also listed as ‘could not be finalised’ if the available information is considered insufficient to conclude on whether the active substance can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009. The following issues or assessments that could not be finalised have been identified, together with the reasons including the associated data gaps where relevant, which are reported directly under the specific issue to which they are related: The risk assessment for the phototoxicity and photomutagenicity potential of fluazaindolizine cannot be concluded (see Section 2): An agreed methodology to assess the risks associated to the exposure to phototoxic and/or photomutagenic pesticide active substances is missing (relevant for all representative uses, see Section 2). The risk assessment for the volatile metabolite IN‐VM862 to humans is not available pending information on inhalation toxicity and a PECair or other non‐dietary human exposure assessment for it (see Sections 2 and 4): The toxicological profile of IN‐VM862 by inhalation should be further addressed (relevant for all representative uses evaluated).A PEC air estimate, or another relevant exposure estimate for the volatile metabolite IN‐VM862 is required (relevant for all representative uses evaluated). The presence of C‐CF3 group in fluazaindolizine indicates that TFA may form during the degradation of the active substance. The formation of TFA as a degradation product of fluazaindolizine was not sufficiently investigated in the environmental compartments (see Sections 3 and 4) (relevant for all the representative uses assessed). Information where investigations are of a sufficient duration and using appropriate analytical techniques to enable the exclusion that the metabolite TFA is formed in soil, surface water systems and present as a residue in plants (rotational crops) were not available (relevant for all representative uses evaluated; see Sections 3 and 4). The groundwater relevance for metabolite IN‐VM862 is still open leading to an issue that could not be finalised (see Sections 2, 3, 4 and 7). Assessment of the aneugenic potential of IN‐VM862 was not available (relevant for all representative uses evaluated).Adsorption studies for metabolite IN‐VM862 conducted using a direct methodology are needed, given the high level of non‐extractable residues observed. The mass balance assessment follows the OECD Test Guideline 106 checklist, explicitly excludes non‐extractable residues from being included in the material balance calculation (EFSA, 2017) (relevant for all representative uses evaluated). The consumer risk assessment could not be finalised since the magnitude of residues from rotated crops is open and thus the livestock exposure assessment cannot be conducted and consequently the risk assessment residue definition for ruminants could not be finalised (see Section 3) Data and/or studies are needed to address realistic scenarios for the uptake of the parent compound and its persistent soil metabolites (IN‐QEK31, IN‐REG72, IN‐F4106, IN‐A5760) by rotated crops, considering multiannual use of the active substance and the resulting accumulated PEC concentrations of all metabolites to evaluate the presented field trials. In case of submission of rotational trials, they need to be covered by valid storage stability studies and validated analytical method, analysing also IN‐REG72 and its glucose conjugate before hydrolysis (see Appendix D) (relevant for all representative uses, see Section 3).A final dietary burden calculation needs to be carried out based on results from valid and reliable residue field trials with primary and rotated crops (relevant for all representative uses, see Section 3).Based on a final dietary burden calculation transfer factors for all feed metabolites should be derived using existing metabolism studies with fluazaindolizine and metabolites, and the ruminant feeding study with fluazaindolizine to consider the relevance of feed metabolites for which animal studies were not available, in order to conclude on the ruminant risk assessment residue definition (relevant for all representative uses, see Section 3). The consumer risk assessment could not be finalised with regard to the unknown nature of residues that might be present in drinking water, consequent to water treatment following abstraction of surface water or groundwater that might contain the active substance and its metabolites (see Sections 3 and 4). Missing sufficient information to assess the impact of water treatment processes on the nature of residues potentially present in surface water and groundwater, when these sources are used for the production of drinking water. In particular, the possible degradation of fluazaindolizine and its potential contribution to the degradation products including TFA during the drinking water processes was not addressed (see Section 4). The environmental exposure assessment could not be finalised as two chromatogram peaks with retention time 2.3 and 31.5 min were not identified in natural water samples during the aqueous photolysis study. The residue definition for risk assessment is open (see Sections 4 and 5). It was not clear whether unidentified chromatographic peaks account more or less than 10% AR in the available aqueous photolysis study. Satisfactory information to identify the two unidentified metabolites was not available. Substance property information (degradation rate and adsorption) was not available. Consequently, the surface water exposure assessments for the two unidentified metabolites were not available (relevant for all the representative uses assessed). The risk assessment for the phototoxicity and photomutagenicity potential of fluazaindolizine cannot be concluded (see Section 2): An agreed methodology to assess the risks associated to the exposure to phototoxic and/or photomutagenic pesticide active substances is missing (relevant for all representative uses, see Section 2). The risk assessment for the phototoxicity and photomutagenicity potential of fluazaindolizine cannot be concluded (see Section 2): An agreed methodology to assess the risks associated to the exposure to phototoxic and/or photomutagenic pesticide active substances is missing (relevant for all representative uses, see Section 2). An agreed methodology to assess the risks associated to the exposure to phototoxic and/or photomutagenic pesticide active substances is missing (relevant for all representative uses, see Section 2). An agreed methodology to assess the risks associated to the exposure to phototoxic and/or photomutagenic pesticide active substances is missing (relevant for all representative uses, see Section 2). The risk assessment for the volatile metabolite IN‐VM862 to humans is not available pending information on inhalation toxicity and a PECair or other non‐dietary human exposure assessment for it (see Sections 2 and 4): The toxicological profile of IN‐VM862 by inhalation should be further addressed (relevant for all representative uses evaluated).A PEC air estimate, or another relevant exposure estimate for the volatile metabolite IN‐VM862 is required (relevant for all representative uses evaluated). The risk assessment for the volatile metabolite IN‐VM862 to humans is not available pending information on inhalation toxicity and a PECair or other non‐dietary human exposure assessment for it (see Sections 2 and 4): The toxicological profile of IN‐VM862 by inhalation should be further addressed (relevant for all representative uses evaluated).A PEC air estimate, or another relevant exposure estimate for the volatile metabolite IN‐VM862 is required (relevant for all representative uses evaluated). The toxicological profile of IN‐VM862 by inhalation should be further addressed (relevant for all representative uses evaluated). The toxicological profile of IN‐VM862 by inhalation should be further addressed (relevant for all representative uses evaluated). A PEC air estimate, or another relevant exposure estimate for the volatile metabolite IN‐VM862 is required (relevant for all representative uses evaluated). A PEC air estimate, or another relevant exposure estimate for the volatile metabolite IN‐VM862 is required (relevant for all representative uses evaluated). The presence of C‐CF3 group in fluazaindolizine indicates that TFA may form during the degradation of the active substance. The formation of TFA as a degradation product of fluazaindolizine was not sufficiently investigated in the environmental compartments (see Sections 3 and 4) (relevant for all the representative uses assessed). Information where investigations are of a sufficient duration and using appropriate analytical techniques to enable the exclusion that the metabolite TFA is formed in soil, surface water systems and present as a residue in plants (rotational crops) were not available (relevant for all representative uses evaluated; see Sections 3 and 4). The presence of C‐CF3 group in fluazaindolizine indicates that TFA may form during the degradation of the active substance. The formation of TFA as a degradation product of fluazaindolizine was not sufficiently investigated in the environmental compartments (see Sections 3 and 4) (relevant for all the representative uses assessed). Information where investigations are of a sufficient duration and using appropriate analytical techniques to enable the exclusion that the metabolite TFA is formed in soil, surface water systems and present as a residue in plants (rotational crops) were not available (relevant for all representative uses evaluated; see Sections 3 and 4). Information where investigations are of a sufficient duration and using appropriate analytical techniques to enable the exclusion that the metabolite TFA is formed in soil, surface water systems and present as a residue in plants (rotational crops) were not available (relevant for all representative uses evaluated; see Sections 3 and 4). Information where investigations are of a sufficient duration and using appropriate analytical techniques to enable the exclusion that the metabolite TFA is formed in soil, surface water systems and present as a residue in plants (rotational crops) were not available (relevant for all representative uses evaluated; see Sections 3 and 4). The groundwater relevance for metabolite IN‐VM862 is still open leading to an issue that could not be finalised (see Sections 2, 3, 4 and 7). Assessment of the aneugenic potential of IN‐VM862 was not available (relevant for all representative uses evaluated).Adsorption studies for metabolite IN‐VM862 conducted using a direct methodology are needed, given the high level of non‐extractable residues observed. The mass balance assessment follows the OECD Test Guideline 106 checklist, explicitly excludes non‐extractable residues from being included in the material balance calculation (EFSA, 2017) (relevant for all representative uses evaluated). The groundwater relevance for metabolite IN‐VM862 is still open leading to an issue that could not be finalised (see Sections 2, 3, 4 and 7). Assessment of the aneugenic potential of IN‐VM862 was not available (relevant for all representative uses evaluated).Adsorption studies for metabolite IN‐VM862 conducted using a direct methodology are needed, given the high level of non‐extractable residues observed. The mass balance assessment follows the OECD Test Guideline 106 checklist, explicitly excludes non‐extractable residues from being included in the material balance calculation (EFSA, 2017) (relevant for all representative uses evaluated). Assessment of the aneugenic potential of IN‐VM862 was not available (relevant for all representative uses evaluated). Assessment of the aneugenic potential of IN‐VM862 was not available (relevant for all representative uses evaluated). Adsorption studies for metabolite IN‐VM862 conducted using a direct methodology are needed, given the high level of non‐extractable residues observed. The mass balance assessment follows the OECD Test Guideline 106 checklist, explicitly excludes non‐extractable residues from being included in the material balance calculation (EFSA, 2017) (relevant for all representative uses evaluated). Adsorption studies for metabolite IN‐VM862 conducted using a direct methodology are needed, given the high level of non‐extractable residues observed. The mass balance assessment follows the OECD Test Guideline 106 checklist, explicitly excludes non‐extractable residues from being included in the material balance calculation (EFSA, 2017) (relevant for all representative uses evaluated). The consumer risk assessment could not be finalised since the magnitude of residues from rotated crops is open and thus the livestock exposure assessment cannot be conducted and consequently the risk assessment residue definition for ruminants could not be finalised (see Section 3) Data and/or studies are needed to address realistic scenarios for the uptake of the parent compound and its persistent soil metabolites (IN‐QEK31, IN‐REG72, IN‐F4106, IN‐A5760) by rotated crops, considering multiannual use of the active substance and the resulting accumulated PEC concentrations of all metabolites to evaluate the presented field trials. In case of submission of rotational trials, they need to be covered by valid storage stability studies and validated analytical method, analysing also IN‐REG72 and its glucose conjugate before hydrolysis (see Appendix D) (relevant for all representative uses, see Section 3).A final dietary burden calculation needs to be carried out based on results from valid and reliable residue field trials with primary and rotated crops (relevant for all representative uses, see Section 3).Based on a final dietary burden calculation transfer factors for all feed metabolites should be derived using existing metabolism studies with fluazaindolizine and metabolites, and the ruminant feeding study with fluazaindolizine to consider the relevance of feed metabolites for which animal studies were not available, in order to conclude on the ruminant risk assessment residue definition (relevant for all representative uses, see Section 3). The consumer risk assessment could not be finalised since the magnitude of residues from rotated crops is open and thus the livestock exposure assessment cannot be conducted and consequently the risk assessment residue definition for ruminants could not be finalised (see Section 3) Data and/or studies are needed to address realistic scenarios for the uptake of the parent compound and its persistent soil metabolites (IN‐QEK31, IN‐REG72, IN‐F4106, IN‐A5760) by rotated crops, considering multiannual use of the active substance and the resulting accumulated PEC concentrations of all metabolites to evaluate the presented field trials. In case of submission of rotational trials, they need to be covered by valid storage stability studies and validated analytical method, analysing also IN‐REG72 and its glucose conjugate before hydrolysis (see Appendix D) (relevant for all representative uses, see Section 3).A final dietary burden calculation needs to be carried out based on results from valid and reliable residue field trials with primary and rotated crops (relevant for all representative uses, see Section 3).Based on a final dietary burden calculation transfer factors for all feed metabolites should be derived using existing metabolism studies with fluazaindolizine and metabolites, and the ruminant feeding study with fluazaindolizine to consider the relevance of feed metabolites for which animal studies were not available, in order to conclude on the ruminant risk assessment residue definition (relevant for all representative uses, see Section 3). Data and/or studies are needed to address realistic scenarios for the uptake of the parent compound and its persistent soil metabolites (IN‐QEK31, IN‐REG72, IN‐F4106, IN‐A5760) by rotated crops, considering multiannual use of the active substance and the resulting accumulated PEC concentrations of all metabolites to evaluate the presented field trials. In case of submission of rotational trials, they need to be covered by valid storage stability studies and validated analytical method, analysing also IN‐REG72 and its glucose conjugate before hydrolysis (see Appendix D) (relevant for all representative uses, see Section 3). Data and/or studies are needed to address realistic scenarios for the uptake of the parent compound and its persistent soil metabolites (IN‐QEK31, IN‐REG72, IN‐F4106, IN‐A5760) by rotated crops, considering multiannual use of the active substance and the resulting accumulated PEC concentrations of all metabolites to evaluate the presented field trials. In case of submission of rotational trials, they need to be covered by valid storage stability studies and validated analytical method, analysing also IN‐REG72 and its glucose conjugate before hydrolysis (see Appendix D) (relevant for all representative uses, see Section 3). A final dietary burden calculation needs to be carried out based on results from valid and reliable residue field trials with primary and rotated crops (relevant for all representative uses, see Section 3). A final dietary burden calculation needs to be carried out based on results from valid and reliable residue field trials with primary and rotated crops (relevant for all representative uses, see Section 3). Based on a final dietary burden calculation transfer factors for all feed metabolites should be derived using existing metabolism studies with fluazaindolizine and metabolites, and the ruminant feeding study with fluazaindolizine to consider the relevance of feed metabolites for which animal studies were not available, in order to conclude on the ruminant risk assessment residue definition (relevant for all representative uses, see Section 3). Based on a final dietary burden calculation transfer factors for all feed metabolites should be derived using existing metabolism studies with fluazaindolizine and metabolites, and the ruminant feeding study with fluazaindolizine to consider the relevance of feed metabolites for which animal studies were not available, in order to conclude on the ruminant risk assessment residue definition (relevant for all representative uses, see Section 3). The consumer risk assessment could not be finalised with regard to the unknown nature of residues that might be present in drinking water, consequent to water treatment following abstraction of surface water or groundwater that might contain the active substance and its metabolites (see Sections 3 and 4). Missing sufficient information to assess the impact of water treatment processes on the nature of residues potentially present in surface water and groundwater, when these sources are used for the production of drinking water. In particular, the possible degradation of fluazaindolizine and its potential contribution to the degradation products including TFA during the drinking water processes was not addressed (see Section 4). The consumer risk assessment could not be finalised with regard to the unknown nature of residues that might be present in drinking water, consequent to water treatment following abstraction of surface water or groundwater that might contain the active substance and its metabolites (see Sections 3 and 4). Missing sufficient information to assess the impact of water treatment processes on the nature of residues potentially present in surface water and groundwater, when these sources are used for the production of drinking water. In particular, the possible degradation of fluazaindolizine and its potential contribution to the degradation products including TFA during the drinking water processes was not addressed (see Section 4). Missing sufficient information to assess the impact of water treatment processes on the nature of residues potentially present in surface water and groundwater, when these sources are used for the production of drinking water. In particular, the possible degradation of fluazaindolizine and its potential contribution to the degradation products including TFA during the drinking water processes was not addressed (see Section 4). Missing sufficient information to assess the impact of water treatment processes on the nature of residues potentially present in surface water and groundwater, when these sources are used for the production of drinking water. In particular, the possible degradation of fluazaindolizine and its potential contribution to the degradation products including TFA during the drinking water processes was not addressed (see Section 4). The environmental exposure assessment could not be finalised as two chromatogram peaks with retention time 2.3 and 31.5 min were not identified in natural water samples during the aqueous photolysis study. The residue definition for risk assessment is open (see Sections 4 and 5). It was not clear whether unidentified chromatographic peaks account more or less than 10% AR in the available aqueous photolysis study. Satisfactory information to identify the two unidentified metabolites was not available. Substance property information (degradation rate and adsorption) was not available. Consequently, the surface water exposure assessments for the two unidentified metabolites were not available (relevant for all the representative uses assessed). The environmental exposure assessment could not be finalised as two chromatogram peaks with retention time 2.3 and 31.5 min were not identified in natural water samples during the aqueous photolysis study. The residue definition for risk assessment is open (see Sections 4 and 5). It was not clear whether unidentified chromatographic peaks account more or less than 10% AR in the available aqueous photolysis study. Satisfactory information to identify the two unidentified metabolites was not available. Substance property information (degradation rate and adsorption) was not available. Consequently, the surface water exposure assessments for the two unidentified metabolites were not available (relevant for all the representative uses assessed). It was not clear whether unidentified chromatographic peaks account more or less than 10% AR in the available aqueous photolysis study. Satisfactory information to identify the two unidentified metabolites was not available. Substance property information (degradation rate and adsorption) was not available. Consequently, the surface water exposure assessments for the two unidentified metabolites were not available (relevant for all the representative uses assessed). It was not clear whether unidentified chromatographic peaks account more or less than 10% AR in the available aqueous photolysis study. Satisfactory information to identify the two unidentified metabolites was not available. Substance property information (degradation rate and adsorption) was not available. Consequently, the surface water exposure assessments for the two unidentified metabolites were not available (relevant for all the representative uses assessed). Critical areas of concern An issue is listed as a critical area of concern if there is enough information available to perform an assessment for the representative uses in line with the uniform principles in accordance with Article 29(6) of Regulation (EC) No 1107/2009 and as set out in Commission Regulation (EU) No 546/2011, and if this assessment does not permit the conclusion that, for at least one of the representative uses, it may be expected that a plant protection product containing the active substance will not have any harmful effect on human or animal health or on groundwater, or any unacceptable influence on the environment. An issue is also listed as a critical area of concern if the assessment at a higher tier level could not be finalised due to lack of information, and if the assessment performed at the lower tier level does not permit the conclusion that, for at least one of the representative uses, it may be expected that a plant protection product containing the active substance will not have any harmful effect on human or animal health or on groundwater, or any unacceptable influence on the environment. An issue is also listed as a critical area of concern if, in the light of current scientific and technical knowledge using guidance documents available at the time of application, the active substance is not expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009. The following critical areas of concern are identified, together with any associated data gaps, where relevant, which are reported directly under the specific critical area of concern to which they are related: No critical areas of concern were identified. Overview of the concerns identified for each representative use considered (Table 5) (If a particular condition proposed to be taken into account to manage an identified risk, as listed in Section 8, has been evaluated as being effective, then ‘risk identified’ is not indicated in Table 5.) In addition to the issues indicated in Table 5 below, the technical material specification could not be proposed and therefore it was not possible to compare with the material used in the testing that was used to derive the toxicological reference values. TABLE 5Overview of concerns reflecting the issues not finalised, critical areas of concerns and the risks identified that may be applicable for some but not for all uses or risk assessment scenarios.Representative useCucumberCarrot1 × 750 g/ha (greenhouses (permanent))1 × 500 g/ha (open field) Operator risk Risk identifiedAssessment not finalisedX2 X2 Worker risk Risk identifiedAssessment not finalisedX2 X2 Resident/bystander risk Risk identifiedAssessment not finalisedX2 X2 Consumer risk Risk identifiedAssessment not finalisedX3,4,5,6 X3,4,5,6 Risk to wild non‐target terrestrial vertebrates * Risk identifiedAssessment not finalisedResidue definition for risk assessment open3 Residue definition for risk assessment open3 Risk to wild non‐target terrestrial organisms other than vertebrates * Risk identifiedAssessment not finalisedResidue definition for risk assessment open3 Residue definition for risk assessment open3 Risk to aquatic organisms * Risk identifiedAssessment not finalisedResidue definition for risk assessment open and exposure assessment3,7 Residue definition for risk assessment open and exposure assessment3,7 Groundwater exposure to active substance Legal parametric value breachedAssessment not finalised Groundwater exposure to metabolites Legal parametric value breached a Parametric value of 10 μg/L b breachedAssessment not finalisedX3,4 X3,4 Note: The superscript numbers relate to the numbered points indicated in Sections 9.1 and 9.2, where relevant. Where there is no superscript number, see Sections 2 to 7 for further information.*For the outcome of the ecotoxicological risk assessment carried out with the provisional residue definition for risk assessment, please refer to pertinent paragraphs in Section 5. a It should be noted that the classification proposed in the context of this evaluation procedure under Regulation (EC) No 1107/2009 concurs with the harmonised classification and labelling in accordance with Regulation (EC) No 1272/2008. b Value for non‐relevant metabolites prescribed in SANCO/221/2000‐rev. 10 final, European Commission (2003). Overview of concerns reflecting the issues not finalised, critical areas of concerns and the risks identified that may be applicable for some but not for all uses or risk assessment scenarios. Note: The superscript numbers relate to the numbered points indicated in Sections 9.1 and 9.2, where relevant. Where there is no superscript number, see Sections 2 to 7 for further information. For the outcome of the ecotoxicological risk assessment carried out with the provisional residue definition for risk assessment, please refer to pertinent paragraphs in Section 5. It should be noted that the classification proposed in the context of this evaluation procedure under Regulation (EC) No 1107/2009 concurs with the harmonised classification and labelling in accordance with Regulation (EC) No 1272/2008. Value for non‐relevant metabolites prescribed in SANCO/221/2000‐rev. 10 final, European Commission (2003). LIST OF OTHER OUTSTANDING ISSUES Remaining data gaps not leading to critical areas of concern or issues not finalised but considered necessary to comply with the data requirements, and which are relevant for some or all of the representative uses assessed at EU level. Although not critical, these data gaps may lead to uncertainties in the assessment and are considered relevant. These data gaps refer only to the representative uses assessed and are listed in the order of the sections: Composition of a co‐formulant and some properties of other two co‐formulants (relevant for all representative uses evaluated; see Section ‘The active substance and the formulation for representative uses’).For three of the components of the formulation for representative uses ‘Salibro’ (also referred to as ‘GF‐3880’), genotoxicity and repeated dose toxicity information over the short‐ and long‐term was not available; therefore, in order to allow a final conclusion on the safety assessment of the formulation for representative uses, genotoxicity and repeated dose toxicity data for these component(s) (short‐ and long‐term) might be considered for further assessment (to be confirmed by Member States when assessing applications for PPP authorisation; relevant for all representative uses evaluated; see Section ‘General aspects’).Data to demonstrate that unknown/unspecified impurities are not present in current manufacturing batches (relevant for all representative uses evaluated; see Section 1).Storage stability data for UVJ12 to cover the length of the stored samples in carrot field trials are needed (relevant for representative use in carrots, see Section 3).An evaluation which of the available residue trials in rotational crops could be used in view of the shortcomings of the missing freezer storage stability data for the analysed soil samples and the overstored crop samples is required. Alternatively, the applicant may also consider providing additional data on freezer storage stability (soil and crops) that cover the actual storage time of samples in the residue trials and demonstrate sufficient freezer storage stability (relevant for all representative uses, see Section 3).Standard hydrolysis studies pertinent for food processing conditions for all the compounds included in the risk assessment residue definition needs to be provided since residues above > 0.01mg/kg were present in carrots (relevant for the representative use in carrots, see Section 3).Storage stability data for fluazaindolizine and all metabolites included in the risk assessment residue definitions for animals supporting the storage conditions and times of animal sample extracts of the animal metabolism studies (relevant for all representative uses, see Section 3).Adsorption studies for fluazaindolizine and its metabolites IN‐F4106, IN‐A5760, IN‐REG72 and IN‐QEK31 (one additional soil) are required to be conducted using a direct methodology, given the high level of non‐extractable residues observed. The mass balance assessment to follow the OECD Test Guideline 106 checklist, with the explicit exclusion of non‐extractable residues from the material balance calculation (EFSA, 2017). Composition of a co‐formulant and some properties of other two co‐formulants (relevant for all representative uses evaluated; see Section ‘The active substance and the formulation for representative uses’). Composition of a co‐formulant and some properties of other two co‐formulants (relevant for all representative uses evaluated; see Section ‘The active substance and the formulation for representative uses’). For three of the components of the formulation for representative uses ‘Salibro’ (also referred to as ‘GF‐3880’), genotoxicity and repeated dose toxicity information over the short‐ and long‐term was not available; therefore, in order to allow a final conclusion on the safety assessment of the formulation for representative uses, genotoxicity and repeated dose toxicity data for these component(s) (short‐ and long‐term) might be considered for further assessment (to be confirmed by Member States when assessing applications for PPP authorisation; relevant for all representative uses evaluated; see Section ‘General aspects’). For three of the components of the formulation for representative uses ‘Salibro’ (also referred to as ‘GF‐3880’), genotoxicity and repeated dose toxicity information over the short‐ and long‐term was not available; therefore, in order to allow a final conclusion on the safety assessment of the formulation for representative uses, genotoxicity and repeated dose toxicity data for these component(s) (short‐ and long‐term) might be considered for further assessment (to be confirmed by Member States when assessing applications for PPP authorisation; relevant for all representative uses evaluated; see Section ‘General aspects’). Data to demonstrate that unknown/unspecified impurities are not present in current manufacturing batches (relevant for all representative uses evaluated; see Section 1). Data to demonstrate that unknown/unspecified impurities are not present in current manufacturing batches (relevant for all representative uses evaluated; see Section 1). Storage stability data for UVJ12 to cover the length of the stored samples in carrot field trials are needed (relevant for representative use in carrots, see Section 3). Storage stability data for UVJ12 to cover the length of the stored samples in carrot field trials are needed (relevant for representative use in carrots, see Section 3). An evaluation which of the available residue trials in rotational crops could be used in view of the shortcomings of the missing freezer storage stability data for the analysed soil samples and the overstored crop samples is required. Alternatively, the applicant may also consider providing additional data on freezer storage stability (soil and crops) that cover the actual storage time of samples in the residue trials and demonstrate sufficient freezer storage stability (relevant for all representative uses, see Section 3). An evaluation which of the available residue trials in rotational crops could be used in view of the shortcomings of the missing freezer storage stability data for the analysed soil samples and the overstored crop samples is required. Alternatively, the applicant may also consider providing additional data on freezer storage stability (soil and crops) that cover the actual storage time of samples in the residue trials and demonstrate sufficient freezer storage stability (relevant for all representative uses, see Section 3). Standard hydrolysis studies pertinent for food processing conditions for all the compounds included in the risk assessment residue definition needs to be provided since residues above > 0.01mg/kg were present in carrots (relevant for the representative use in carrots, see Section 3). Standard hydrolysis studies pertinent for food processing conditions for all the compounds included in the risk assessment residue definition needs to be provided since residues above > 0.01mg/kg were present in carrots (relevant for the representative use in carrots, see Section 3). Storage stability data for fluazaindolizine and all metabolites included in the risk assessment residue definitions for animals supporting the storage conditions and times of animal sample extracts of the animal metabolism studies (relevant for all representative uses, see Section 3). Storage stability data for fluazaindolizine and all metabolites included in the risk assessment residue definitions for animals supporting the storage conditions and times of animal sample extracts of the animal metabolism studies (relevant for all representative uses, see Section 3). Adsorption studies for fluazaindolizine and its metabolites IN‐F4106, IN‐A5760, IN‐REG72 and IN‐QEK31 (one additional soil) are required to be conducted using a direct methodology, given the high level of non‐extractable residues observed. The mass balance assessment to follow the OECD Test Guideline 106 checklist, with the explicit exclusion of non‐extractable residues from the material balance calculation (EFSA, 2017). Adsorption studies for fluazaindolizine and its metabolites IN‐F4106, IN‐A5760, IN‐REG72 and IN‐QEK31 (one additional soil) are required to be conducted using a direct methodology, given the high level of non‐extractable residues observed. The mass balance assessment to follow the OECD Test Guideline 106 checklist, with the explicit exclusion of non‐extractable residues from the material balance calculation (EFSA, 2017). ABBREVIATIONS active substance acute acceptable operator exposure level acceptable daily intake acceptable operator exposure level applied radioactivity acute reference dose body weight classification and labelling chromosomal aberration draft assessment report period required for 50% dissipation (define method of estimation) period required for 90% dissipation (define method of estimation) oestrogen, androgen and steroidogenesis modalities European Chemicals Agency endocrine disruption European Economic Community Food and Agriculture Organization of the United Nations Forum for the Co‐ordination of Pesticide Fate Models and their Use Good Agricultural Practice health based guidance values high‐performance liquid chromatography coupled with tandem mass spectrometry high temperature hydrolysis international estimated daily intake international estimated short‐term intake International Organization for Standardization International Union of Pure and Applied Chemistry in vitro comparative metabolism Joint Meeting of the FAO Panel of Experts on Pesticide Residues in Food and the Environment and the WHO Expert Group on Pesticide Residues (Joint Meeting on Pesticide Residues) organic carbon linear adsorption coefficient Freundlich organic carbon adsorption coefficient lethal concentration, median limit of quantification maximum residue level Member State no observed adverse effect level Organisation for Economic Co‐operation and Development plant‐back interval persistence bioaccumulation toxicity predicted environmental concentration predicted environmental concentration in air pF value of 2 (suction pressure that defines field capacity soil moisture) per‐ and polyfluoroalkyl substances personal protective equipment quantitative structure–activity relationship quick, easy, cheap, effective, rugged and safe risk assessment regulatory acceptable concentration Renewal Assessment Report residue definition Registration, Evaluation, Authorisation of Chemicals Regulation risk mitigation measure rapporteur Member State suspension concentrate single first‐order simplified molecular‐input line‐entry system thyroid trifluoroacetic acid ultraviolet World Health Organization REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2021‐00293 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. Supporting information APPENDIX B List of end points for the active substance and the formulation for representative uses